Atlas Genetics, a British molecular diagnostics startup that creates rapid point-of-care tests for infectious diseases like chlamydia, will launch U.S. clinical trials with a $20 million Series C round.
It will also expand its test offerings in the sexually transmitted infection and hospital acquired infection markets, Atlas said in a release.
The company’s io(R) molecular diagnostic cartridge contains all the necessary reagents to accept unprocessed clinical samples – testing them for up to 24 different conditions in under 30 minutes, the company says.
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
“This will enable clinicians to test and commence treatment within the same appointment and ensure much improved compliance, particularly in the area of STIs, where a significant proportion of patients fail to return for test results or follow-on treatment,” Atlas Genomics said in a release.
This follows a Series B round of $25 million. The recent dollars come from new investor RMI Partners, as well as existing investors Novartis Venture Funds, Consort Medical, Johnson & Johnson Innovation, LSP, BB Biotech Ventures and South West Ventures Fund.